CHICAGO (GenomeWeb) – NantHealth, fresh off a tough 2017 that saw the company cut 300 jobs and face a series of lawsuits related to its 2016 initial public offering, is betting on new technology and assays to carry it into the future.
CHICAGO (GenomeWeb) – NantHealth, fresh off a tough 2017 that saw the company cut 300 jobs and face a series of lawsuits related to its 2016 initial public offering, is betting on new technology and assays to carry it into the future.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.